Ranibizumab
Scheme
USAN
ATC (Anatomical Therapeutic Chemical Classification)
S01LA04
CAS registry number (Chemical Abstracts Service)
0347396-82-1
Chemical Formula
C2158-H3282-N562-O681-S12
Molecular Weight
48349
Therapeutic Categories
Ophthalmic agent
Monoclonal antibody
Treatment of neovascular (wet) age-related macular degeneration
Angiogenesis inhibitor
Treatment of diabetic retinopathy
Vascular endothelial growth factor (VEGF) antagonist
Chemical Name
immunoglobulin G1, anti-(human vascular endotelial growt factor) Fab fragment (human - mouse monoclonal rhuFAB V2 gamma1-chain), disulfide wit human-mouse monoclonal rhuFAB V2 light chain (USAN)
Foreign Names
- Ranibizumabum (Latin)
- Ranibizumab (German)
- Ranibizumab (French)
- Ranibizumab (Spanish)
Generic Names
- Ranibizumab (OS: USAN, BAN)
- Ranibizumab (Genetical Recombination) (OS: JAN)
- AMD Fab (IS: Genentech)
- rhuFab V2 (IS)
Brand Names
- Lucentis
Genentech, United States; Grupo Novartis, Spain; Haemato Pharm, Austria; Novartis, Argentina; Novartis, Bosnia & Herzegowina; Novartis, Belgium; Novartis, Bahrain; Novartis, Chile; Novartis, Colombia; Novartis, Czech Republic; Novartis, Ecuador; Novartis, Egypt; Novartis, Finland; Novartis, France; Novartis, Georgia; Novartis, Greece; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Japan; Novartis, South Korea; Novartis, Lebanon; Novartis, Lithuania; Novartis, Mexico; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Poland; Novartis, Portugal; Novartis, Serbia; Novartis, Sweden; Novartis, Slovakia; Novartis, Thailand; Novartis, Tunisia; Novartis, Turkey; Novartis, Taiwan; Novartis AH, South Africa; Novartis Europharm, Austria; Novartis Europharm, Denmark; Novartis Europharm, Slovenia; Novartis Farma, Italy; Novartis Healthcare, Philippines; Novartis Ophthalmics, Singapore; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharma, Russian Federation; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
